289 related articles for article (PubMed ID: 26293521)
1. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
Wei KK; Zhang LR
Clin Drug Investig; 2015 Sep; 35(9):583-91. PubMed ID: 26293521
[TBL] [Abstract][Full Text] [Related]
2. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men.
Yang G; Fu Z; Chen X; Yuan H; Yang H; Huang Y; Ouyang D; Tan Z; Tan H; Huang Z; Zhou H
Clin Ther; 2011 Dec; 33(12):2060-70. PubMed ID: 22177374
[TBL] [Abstract][Full Text] [Related]
3. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
Mol Diagn Ther; 2014 Jun; 18(3):323-31. PubMed ID: 24430948
[TBL] [Abstract][Full Text] [Related]
4. Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin.
Wei KK; Zhang LR; Zhang Y; Hu XJ
J Clin Pharm Ther; 2011 Dec; 36(6):725-33. PubMed ID: 21128988
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
6. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.
Zhang JJ; Zhang H; Ding XL; Ma S; Miao LY
Eur J Clin Pharmacol; 2013 Apr; 69(4):807-12. PubMed ID: 23097010
[TBL] [Abstract][Full Text] [Related]
7. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.
Li YP; Zhang LR; Jia M; Hu XJ
J Clin Pharmacol; 2011 Feb; 51(2):181-8. PubMed ID: 20519697
[TBL] [Abstract][Full Text] [Related]
8. Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
Kivistö KT; Niemi M; Schaeffeler E; Pitkälä K; Tilvis R; Fromm MF; Schwab M; Eichelbaum M; Strandberg T
Pharmacogenetics; 2004 Aug; 14(8):523-5. PubMed ID: 15284534
[TBL] [Abstract][Full Text] [Related]
9. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
10. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.
Willrich MA; Hirata MH; Genvigir FD; Arazi SS; Rebecchi IM; Rodrigues AC; Bernik MM; Dorea EL; Bertolami MC; Faludi AA; Hirata RD
Clin Chim Acta; 2008 Dec; 398(1-2):15-20. PubMed ID: 18727922
[TBL] [Abstract][Full Text] [Related]
11. Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin.
Cai G; Zhang B; Shi G; Weng W; Yang L; Xue S
Lipids Health Dis; 2016 Sep; 15(1):148. PubMed ID: 27600285
[TBL] [Abstract][Full Text] [Related]
12. POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia.
Drogari E; Ragia G; Mollaki V; Elens L; Van Schaik RH; Manolopoulos VG
Pharmacogenomics; 2014 Dec; 15(16):1963-72. PubMed ID: 25521355
[TBL] [Abstract][Full Text] [Related]
13. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
14. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
Clin Pharmacol Ther; 2005 Nov; 78(5):551-8. PubMed ID: 16321621
[TBL] [Abstract][Full Text] [Related]
15. [PPARdelta + 294T/C gene polymorphism related to plasma lipid, obesity and left ventricular hypertrophy in subjects with metabolic syndrome].
Yan ZC; Shen CY; Zhong J; Wang L; Ni YX; Nie H; Zhu ZM
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Jun; 33(6):529-33. PubMed ID: 16053787
[TBL] [Abstract][Full Text] [Related]
16. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.
Kadam P; Ashavaid TF; Ponde CK; Rajani RM
J Clin Pharm Ther; 2016 Jun; 41(3):329-33. PubMed ID: 26932749
[TBL] [Abstract][Full Text] [Related]
17. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
Shabana MF; Mishriki AA; Issac MS; Bakhoum SW
Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857
[TBL] [Abstract][Full Text] [Related]
18. [Effects of genetic variations of cholesteryl ester transfer protein on atorvastatin treatment efficacy and clinical outcomes in patients with coronary artery disease].
Gao J; Cong HL; Mao YM; Liu Y; Zhang N; Chen Q; Liu T; Cui RZ
Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(28):2195-9. PubMed ID: 24169327
[TBL] [Abstract][Full Text] [Related]
19. Interactions of the apolipoprotein C-III 3238C>G polymorphism and alcohol consumption on serum triglyceride levels.
Ruixing Y; Yiyang L; Meng L; Kela L; Xingjiang L; Lin Z; Wanying L; Jinzhen W; Dezhai Y; Weixiong L
Lipids Health Dis; 2010 Aug; 9():86. PubMed ID: 20716347
[TBL] [Abstract][Full Text] [Related]
20. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin.
Jiang XY; Zhang Q; Chen P; Li SY; Zhang NN; Chen XD; Wang GC; Wang HB; Zhuang MQ; Lu M
J Clin Pharm Ther; 2012 Dec; 37(6):719-23. PubMed ID: 22882727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
